Thyroid hormone receptor (TR)alpha and trbeta expression in breast cancer

Histology and Histopathology

Volumn 28, Issue 2, 2013, Pages 227-237

  Ditsch, Nina ^a   Toth, Bettina ^b   Himsl, Isabelle ^a   Lenhard, Miriam ^a   Ochsenkühn, Robert ^a   Friese, Klaus ^a   Mayr, Doris ^c   Jeschke, Udo ^c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

Breast cancer; Immunohistochemistry; Thyroid hormone receptor alpha; Thyroid hormone receptor beta

Indexed keywords

THYROID HORMONE RECEPTOR ALPHA; THYROID HORMONE RECEPTOR BETA; TUMOR MARKER;

AGED; ARTICLE; BREAST TUMOR; CELL NUCLEUS; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL NUCLEUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; THYROID HORMONE RECEPTORS ALPHA; THYROID HORMONE RECEPTORS BETA; TUMOR MARKERS, BIOLOGICAL;

EID: 84873828821     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Beatson GT. (1896). On the treatment of inoperable cancer of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 2, 104-165
2. Boecker W. (2002). WHO classification of breast tumors and tumors of the female genital organs: pathology and genetics. Verh. Dtsch. Ges. Pathol. 86, 116-119.
3. Bruning P., Bonfrer J., Jong-Bakker M. de, Nooyen W. and Brugers M. (1985). Primary hypothyroidism in breast cancer patients with irraditated supraclavicular lymph nodes. Br. J. Cancer 51, 659-663.
4. Cerbon M.A., Pichon M.F. and Milgrom E. (1981). Thyroid hormone receptors in Human breast cancer. Cancer Res. 41, 4167-4173.
5. Conde I., Paniagua R., Zamora J., Blánquez M.J., Fraile B., Ruiz A. and Arenas M.I. (2006). Influence of thyroid hormone receptors on breast cancer cell proliferation. Ann. Oncol. 17, 60-64.
6. De Sombre E.R., Green G.L. and Jensen EV. (1978). Estrophilin and endocrine responsiveness of breast cancer. Prog. Cancer Res. Ther. 10, 1-14.
7. Ditsch N., Liebhardt S., von Koch F., Lenhard M., Vogeser M., Spitzweg C., Gallwas J. and Toth B. (2010). Thyroid function in breast cancer patients. Anticancer Res. 30, 1713-1717.
8. Elston C.W. and Ellis I.O. (2002). Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19, 403-410.
9. Fasco M.J., Keyomarsi K., Arcaro K.F. and Gierthy J.F. (2000). Expression of an estrogen receptor alpha variant protein in cell lines and tumours. Mol. Cell. Endocrinol. 166, 156-169.
10. Giani C., Fierabracci P., Bonacci R., Gigliotti A., Campani D., De Negri F., Cecchetti D., Martino E. and Pinchera A. (1996). Relationship between breast cancer and thyroid disease: relevance of autoimmune thyroid disorders in breast malignancy. J. Clin. Endocrinol. Metab. 81, 990-994.
11. Jeschke U., Bischof A. and Speer R. (2005). Development of monoclonal and polyclonal antibodies and an ELISA for the determination of glycodelin in human serum, amniotic fluid and cystic fluid of benign and malignant ovarian tumours. Anticancer Res. 25, 1581-1589.
12. Jiskra J., Limanova Z., Barkmanova J. and Friedmanova Z. (2003). Prevalence of autoimmune thyroid diseases in women with breast cancer in comparison with colorectal cancer. Klinicka onkologie 16, 149-153.
13. Knight W.A., Livingston R.B., Gregory E.J. and McGuire W.L. (1977). Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res. 37, 4669-4671.
14. Kuijpens J.L.P., Nyklictek I., Louwman M.W.J., Weetman T.A.P., Pop V.J.M. and Coebergh J.W.W. (2005). Hypothyroidism might be related to breast cancer in post-menopausal women. Thyroid 5, 1253-1259.
15. Lazar M.A. (1993). Thyroid hormone receptors: multiple forms, multiple possibilities. Review. Endocr. Rev. 14, 184-193.
16. Lemaire M. and Baugnet-Mahieu L. (1986). Nuclar thyroid hormone receptors in human cancer tissues. Anticancer Res. 6, 695-700.
17. Li J., Lin Q., Yoon H.G., Huang Z.Q., Strahl B.D., Allis C.D. and Wong J. (2002a). Involvement of histone methylation and phosphorylation in regulation of transcription by thyroid hormone receptor. Mol. Cell. Biol. 22, 5688-5697.
18. Li Z., Meng Z.H., Chandrasekaran R., Kuo W.L., Collins C.C., Gray J.W. and Dairkee S.H. (2002b). Biallelic inactivation of the thyroid hormone receptor beta1 gene in early stage breast cancer. Cancer Res. 62, 1939-1943.
19. Limanova Z., Barkmanova J. and Friedmanova Z. (1998). The fquent incidence of thyropathies in women with breast carcinoma. Vntir Lek 44, 76-82.
20. Ling Y., Xu X., Hao J., Ling X., Du X., Liu X. and Zhao X. (2010). Aberrant methylation of the TRB gene in tissue and plasma of breast cancer patients. Cancer Genet. Cytogenet. 15, 196, 140-145.
21. Loeser A.A. (1954). New therapy for prevention of postoperative recurrences in genital and breast cancer: six years'study of prophylactic thyroid treatment. Br. Med. J. 2, 1380-1383.
22. López-Barahona M., Fialka I., González-Sancho J.M., Asunción M., González M., Iglesias T., Bernal J., Beug H. and Muñoz A. (1995). Thyroid hormone regulates stromelysin expression, protease secretion and the morphogenetic potential of normal polarized mammary epithelial cells. EMBO J. 14,1145-1455.
23. Martinez M.B., Ruan M. and Fitzpatrick L.A. (2000). Altered response to thyroid hormones by prostate and breast cancer cells. Cancer Chemother. Pharmacol. 45, 93-102.
24. Martinez-Iglesias O., Garcia-Silva S., Tenbaum S.P., Regadera J., Larcher F., Paramio J.M., Vennström B. and Aranda A. (2009). Thyroid hormone receptor beta1 acts as a potent suppressor of tumour invasiveness and metastasis. Cancer Res. 69, 501.
25. Maynard P.V., Blamey R.W., Elston C.W., Haybittle J.L. and Griffiths K. (1978). Estrogen receptor assay in primary breast cancer and early recurrence of the disease. Cancer Res. 38, 5292-5295.
26. Muñoz A. and Bernal J. (1997). Biological activities of thyroid hormone receptors. Review. Eur. J. Endocrinol. 137, 433-445.
27. Mylonas I., Makovitzky J., Jeschke U., Briese V., Friese K. and Gerber B. (2005). Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) versus invasive breast cancer alone. Anticancer Res. 25, 1719-1723.
28. Osborne C.K. and McGuire W.L. (1979). The use of steroid hormone receptors in the treatment of human breast cancer: a review. Bull. Cancer 66, 203-210
29. Pichon M.F., Pallud C., Brunet M. and Milgrom E. (1980). Relationship of presence of progesterone receptors to prognosis in early breast cancer. Cancer Res. 40, 3357-3360
30. Rasmusson B., Feldt-Rasmussen U., Hegedus L., Perrild H., Bech K. and Hoier-Madsen M. (1987). Thyroid function in patients with breast cancer. Eur. J. Cancer Clin. Oncol. 23, 553-556.
31. Remmele W. and Stegner H.E. (1987). Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8, 138-140.
32. Schernhammer E.S., Laden F., Speizer F.E., Willett W.C., Hunter D.J., Kawachi I. and Colditz G.A. (2001). Rotatine night shifts and risk of breast cancer in women participating in the Nurses'Health Study. J. Natl. Cancer. Inst. 93, 1563-1568.
33. Shering S.G., Zbar A.P., Moriarty M., McDermott E.W., O'Higgins N.J. and Smyth P.P.A. (1996).Thyroid disorders and breast cancer. Eur. J. Cancer Prev. 5, 504-506.
34. Silva J.M., Domínguez G., González-Sancho J.M., García J.M., Silva J., García-Andrade C., Navarro A., Muñoz A. and Bonilla F. (2002). Expression of thyroid hormone receptor/erbA genes is altered in human breast cancer. Oncogene 21, 4307-4316.
35. Smallridge R.C. and Latham K.R. (1980). Nuclear thyroid hormone receptor in human breast tumours. Clin. Res. 28, 421.
36. Smyth P.P.A. (1997). The thyroid and breast cancer: a significant association? Ann. Med. 29, 189-191.
37. Smyth P.P.A., Shering S.G., Kilbane M.T., Murray M.J., McDermot E.W.N., Smith D.F. and O'Higgings N.J. (1998). Serum thyroid peroxidase autoantibodies, thyroid volume, and outcome in breast carcinoma. J. Clin. Endocrinol. Metab. 83, 2711-2716.
38. Truss M. and Beato M. (1993). Steroid hormone receptors: interaction with deoxyribonucleic acid and transcription factors. Review. Endocr. Rev. 14, 459-479.
39. Turken O., Narln Y., Demirbas S., Onde M.E., Sayan O., Kandemir E.G., Yaylaci M. and Ozturk A. (2003). Breast cancer in association with thyroid disorder. Breast Cancer Res. 5, R110-R113.
40. Yokoe T., PIino Y., Takei H., Horiguchi J., Koibuchi Y., Maemura M., Ohwada S. and Morishita Y. (1996). Relationship between thyroidpituitary function and response to therapy in patients with recurrent breast cancer. Anticancer Res. 16, 2069-2072.
41. Zhou-Li F., Albaladejo V., Joly-Pharaboz M.O., Nicolas B. and Andre J. (1992). Antiestrogens prevent the stimulatory effects of Ltriiodothyronine on cell proliferation. Endocrinology 130, 1145-1152.